Skip to main navigation

Investor Relations

Overview
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials
- SEC Filings
- Quarterly Results
Governance
IR Resources

Press Releases

Year

Jun 20, 2024

Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial

Jun 06, 2024

Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial

May 29, 2024

Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

May 20, 2024

Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site

Apr 24, 2024

Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Apr 02, 2024

Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Mar 19, 2024

Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial

Mar 01, 2024

Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Feb 28, 2024

Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th

Feb 14, 2024

Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 22

Investor Tools

Print

RSS Feeds

Email Alerts

Investor Contact

Copyright © 2024 Kiromic BioPharma, Inc. All rights reserved.